Mycobacterium churgai infection
Mycobacterium szulgai was confirmed as a human pathogen by Marks in 1972. It is a dark-colored mycobacterium. It produces light gas when cultured at 25°C, dark color when cultured at 37°C, and does not grow at 42°C. The colonies are orange and grow slowly. The pathogenesis is not very clear. The clinical manifestations are varied. Skin lesions are disseminated painless inflammatory nodules. Positive mycobacterial culture of skin lesion tissue can be diagnosed. The combination of ethionamide, isoniazid and rifampicin is effective.
-
Site of disease:
Lung skin -
Infectious :
Not contagious -
Frequent population:
All groups -
Related symptoms:
Skin atrophy and pigmentation pulmonary infection nodules secondary infection pigmentation
Related Drugs
Ethambutol Hydrochloride Tablets
Indication: It is suitable for the treatment of pulmonary tuberculosis caused by Mycobacterium tuberculosis in combination with other anti-tuberculosis drugs. It can also be used to treat tuberculous meningitis and atypical mycobacterial infections.
Manufacturer:
Shenyang Red Flag Pharmaceutical Co., Ltd.
Prothionamide Enteric-coated Tablets
Indication: This product is only effective against mycobacteria. It is used in combination with other anti-tuberculosis drugs for patients with tuberculosis who have not responded to first-line treatment with drugs (such as streptomycin, isoniazid, rifampicin and ethambutol).
Pyrazinamide Capsules
Indication: This product is only effective against mycobacteria and is used in combination with other anti-tuberculosis drugs (such as streptomycin, isoniazid, rifampicin and ethambutol) to treat tuberculosis.
Manufacturer:
Liaoning Wohua Kangchen Pharmaceutical Co., Ltd.
Related Ingredients